The Psychedelic Genome Project (PGP) aims to collect genetic and epigenetic data, along with data on the psychedelic, clinical, and any potential adverse effects of psychedelics.
We collect data from people receiving psychedelic treatments (e.g., at a ketamine clinic), other psychedelic services (such as in Oregon and Colorado, where state law permits psilocybin services), and participants in psychedelic clinical trials (like this MDMA trial).
Our Goals are to:
- Explore the potential of different psychedelics for treating various mental health disorders, paving the way for safer, more effective therapies that could alleviate suffering for millions of people worldwide.
- Identify genetic and epigenetic biomarkers that can predict psychedelic effects, enabling personalized psychedelic therapies tailored to each individual.
- Uncover the biological and psychological mechanisms underlying the effects of psychedelics, offering insight into how mental health disorders emerge and how they might be more effectively treated.
We are currently recruiting!
Psychedelic Genome Project – Ketamine
We currently partner with several local Arizona ketamine clinics to collect biosamples (saliva) and data on the psychedelic, clinical, and any potential adverse effects of ketamine administration. Our providers employ a diverse array of ketamine administration protocols, permitting assessment of current clinical practices surrounding ketamine.
Our Clinical Partners:
- Advanced Wellness and Pain
- Alevea Mental Health
- CAP Healing
- Iridescent Counseling/Guided Journeys
- Kadelyx
Psychedelic Genome Project – Psilocybin
We also have active protocols to collect data from the following three locations, where regulated psilocybin services are available:
The Oregon Psilocybin Services Act established a structured licensing and regulatory system for psilocybin services that offers a unique opportunity to study the effects of psilocybin in a controlled environment. It was reported that over 700 people used Oregon’s psilocybin service centers in 2023 (the first year it was available), making this the largest group of people receiving regulated psilocybin services.
Likewise, Colorado passed Proposition 122, under which state-licensed facilities are predicted to be able to begin administering psilocybin and psilocin by late 2024. Each psilocybin service center is state-licensed to train facilitators that provide safety oversight, and the psilocybin delivered by each center is produced by state-licensed manufacturing laboratories that ensure drug purity.
In the Netherlands, the Supreme Court declared psilocybin-containing truffles, a natural occurring substance, as exempt from the 2008 Opium Act. This exemption allows licensed providers in the Netherlands to sell truffles. Licensed providers are regulated and must comply with age restrictions, dosage guidance, and provide consumer education.